389 related articles for article (PubMed ID: 33925707)
1. Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.
Liu L; O'Kelly D; Schuetze R; Carlson G; Zhou H; Trawick ML; Pinney KG; Mason RP
Molecules; 2021 Apr; 26(9):. PubMed ID: 33925707
[TBL] [Abstract][Full Text] [Related]
2. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
[TBL] [Abstract][Full Text] [Related]
3. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy.
Kremmidiotis G; Leske AF; Lavranos TC; Beaumont D; Gasic J; Hall A; O'Callaghan M; Matthews CA; Flynn B
Mol Cancer Ther; 2010 Jun; 9(6):1562-73. PubMed ID: 20515948
[TBL] [Abstract][Full Text] [Related]
4. Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.
Kim KW; Lee JM; Jeon YS; Lee IJ; Choi Y; Park J; Kiefer B; Kim C; Han JK; Choi BI
Invest New Drugs; 2013 Oct; 31(5):1097-106. PubMed ID: 23299389
[TBL] [Abstract][Full Text] [Related]
5. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ji YT; Liu YN; Liu ZP
Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
[TBL] [Abstract][Full Text] [Related]
6. Current Advances of Tubulin Inhibitors in Nanoparticle Drug Delivery and Vascular Disruption/Angiogenesis.
Banerjee S; Hwang DJ; Li W; Miller DD
Molecules; 2016 Nov; 21(11):. PubMed ID: 27827858
[TBL] [Abstract][Full Text] [Related]
7. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
[TBL] [Abstract][Full Text] [Related]
8. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091.
Canela MD; Noppen S; Bueno O; Prota AE; Bargsten K; Sáez-Calvo G; Jimeno ML; Benkheil M; Ribatti D; Velázquez S; Camarasa MJ; Díaz JF; Steinmetz MO; Priego EM; Pérez-Pérez MJ; Liekens S
Oncotarget; 2017 Feb; 8(9):14325-14342. PubMed ID: 27224920
[TBL] [Abstract][Full Text] [Related]
9. Vascular disrupting agents in clinical development.
Hinnen P; Eskens FA
Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
[TBL] [Abstract][Full Text] [Related]
10. Combination of vascular disrupting agents and ionizing radiation.
Clémenson C; Chargari C; Deutsch E
Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
[TBL] [Abstract][Full Text] [Related]
11. Vascular targeting agents.
Pilat MJ; McCormick J; LoRusso PM
Curr Oncol Rep; 2004 Mar; 6(2):103-10. PubMed ID: 14751087
[TBL] [Abstract][Full Text] [Related]
12. Combretastatins: more than just vascular targeting agents?
Greene LM; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2015 Nov; 355(2):212-27. PubMed ID: 26354991
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
Baguley BC
Clin Lung Cancer; 2011 Mar; 12(2):81-6. PubMed ID: 21550553
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitors of microtubule polymerization- new natural compounds as potential anti-cancer drugs].
Rogalska A; Miśkiewicz K; Marczak A
Postepy Hig Med Dosw (Online); 2015 May; 69():571-85. PubMed ID: 25983296
[TBL] [Abstract][Full Text] [Related]
16. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
17. Smart Nanotherapeutic Targeting of Tumor Vasculature.
Li Z; Di C; Li S; Yang X; Nie G
Acc Chem Res; 2019 Sep; 52(9):2703-2712. PubMed ID: 31433171
[TBL] [Abstract][Full Text] [Related]
18. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
Kanthou C; Tozer GM
Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
[TBL] [Abstract][Full Text] [Related]
19. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
[TBL] [Abstract][Full Text] [Related]
20. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]